Recombinant botulinum neurotoxins with increased duration of effect

Patent metadata

Field	Value
Publication number	US-11155802-B2
Application number	US-201716498257-A
Country	US
Kind code	B2
Filing date	Jul 6, 2017
Priority date	Jul 6, 2017
Publication date	Oct 26, 2021
Grant date	Oct 26, 2021

Abstract

This invention relates to novel recombinant botulinum neurotoxins serotype A exhibiting both (i) an increased duration of effect and (ii) a high specific biological activity. These novel recombinant botulinum neurotoxins comprise at least two additional domains consisting of proline, alanine and an additional amino acid residue and at least one amino acid modification which is located at the alpha-exosite or at the beta-exosite of the light chain of the neurotoxin. The invention further relates to novel recombinant single-chain precursor botulinum neurotoxins and compositions comprising the recombinant botulinum neurotoxin with an increased duration of effect and a high specific biological activity.

First claim

The invention claimed is:

1. A recombinant botulinum neurotoxin serotype A comprising at least two domains wherein each domain comprises an amino acid sequence comprising at least 50 amino acid residues, wherein said amino acid sequence comprises at least one proline, at least one alanine and at least one additional amino acid residue, selected from the group consisting of serine, threonine, tyrosine and glutamine, wherein the neurotoxin further comprises at least one amino acid modification which is located at the alpha-exosite and/or at the beta-exosite of the light chain of the neurotoxin,
wherein the said at least one amino acid modification is located at at least one position selected from D102, T109, K340, I348, N353, and K356 of the alpha-exosite, or at at least one position selected from G169, T220, P239, and S254 of the beta-exosite.

2. The recombinant neurotoxin of claim 1 , wherein six amino acid modifications are located at the alpha-exosite at positions D102, T109, K340, I348, N353, K356, wherein these amino acids are substituted as follows D102F, T109R, K340M, I348L, N353M, K356R.

3. The recombinant neurotoxin of claim 1 , wherein four amino acid modifications are located at the beta-exosite at positions G169, T220, P239, S254, wherein these amino acids are substituted as follows G169I, T220R, P239M, S254T.

4. The recombinant neurotoxin of claim 2 , wherein the neurotoxin comprises two domains wherein each domain comprises an amino acid sequence consisting of between 70 and 260 amino acid residues, wherein said amino acid sequence consists of proline, alanine and serine residues.

5. A composition comprising the recombinant neurotoxin of claim 1 and a solvent or excipient.

6. A pharmaceutical composition comprising the recombinant neurotoxin of claim 1 and one or more pharmaceutically acceptable carriers.

7. A method for the generation of a recombinant neurotoxin according to claim 1 , comprising the step of obtaining a recombinant nucleic acid sequence encoding a recombinant single-chain precursor neurotoxin by the insertion of a nucleic acid sequence encoding said at least two domains consisting of proline, alanine and additional amino acid residues, selected from the group consisting of serine, threonine, tyrosine and glutamine residues into a nucleic acid sequence encoding a parental clostridial neurotoxin and by modifying the nucleic acid sequence encoding a parental botulinum neurotoxin at the alpha-exosite and/or at the beta-exosite of the light chain.

8. A recombinant single-chain neurotoxin, which is a precursor for the recombinant neurotoxin of claim 1 .

9. A nucleic acid sequence encoding the recombinant single-chain clostridial neurotoxin of claim 8 .

10. A vector comprising the nucleic acid sequence of claim 9 .

11. A recombinant host cell comprising the nucleic acid sequence of claim 9 .

12. A recombinant host cell comprising the vector of claim 10 .

13. The recombinant neurotoxin of claim 3 , wherein the neurotoxin comprises two domains wherein each domain comprises an amino acid sequence consisting of between 70 and 260 amino acid residues, wherein said amino acid sequence consists of proline, alanine and serine residues.

Assignees

• Merz Pharma Gmbh & Co Kgaa

Inventors

• FREVERT Jürgen
• Hofmann Fred
• Jurk Marcel
• López De La Paz Manuela
• Scheps Daniel

Classifications

• C07K14/33 Primary

  from Clostridium (G) · CPC title

• C12Y304/24069

  Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12N9/52 Primary

  derived from bacteria {or Archaea} · CPC title